Unither Taps Specialty Chemicals Veteran to Lead CDMO Expansion

Unither Pharmaceuticals has appointed Henrik Krüpper as its new Chief Executive Officer, a leadership change that arrives as the contract manufacturer moves deeper into a facility expansion cycle begun in early 2026. For plant heads and QA directors working within the CDMO supply chain, the selection of an executive whose career spans both specialty chemicals and pharmaceuticals signals a deliberate strategic posture at a company scaling its manufacturing footprint.

Krüpper brings cross-sector experience accumulated across the specialty chemicals and pharmaceuticals industries, including a tenure at Evonik, formerly known as Degussa. That background is notable for a CDMO operating under the dual pressures of GMP compliance and commercial throughput: executives who have navigated chemical process development alongside pharmaceutical manufacturing tend to approach process validation and technology transfer with a broader operational lens than those formed exclusively within drug manufacturing environments.

Unither Pharmaceuticals operates as a pharmaceutical contract manufacturer with a specialization in its defined dosage form segments. In January 2026, the group launched construction on a new facility, a capital commitment that will require sustained leadership continuity through qualification, validation, and eventual regulatory submission cycles under frameworks including 21 CFR Part 211 and ICH Q10. Krüpper's appointment positions him to oversee that build-out from an early stage, giving incoming leadership direct influence over site design decisions that will shape sterility assurance and process validation strategies for years ahead.

For contract manufacturing organizations at this stage of capacity expansion, the CEO transition introduces both continuity risk and strategic opportunity. Clients with active technology transfer agreements or pending batch record reviews will be monitoring how quickly Krüpper establishes operational priorities and whether the facility timeline holds against its original construction schedule.

Source: Pharmaceutical Industry News, published 28 April 2026, via EIN News.